ved for symptomatic relief in the treatment of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis in patients at risk of developing a non-steroidal anti-inflammatory drug-associated gastric and/or duodenal ulcers. Xylocaine (lidocaine) is a short-acting local anaesthetic for topical and regional anaesthesia. Zomig (zolmitriptan) is used for the acute treatment of migraine, plus for the acute treatment of cluster headache in the European Union. Zomig is available in three formulations, such as oral tablet, orally dispersible tablet, and nasal spray. Gastrointestinal Marketed Products Entocort (budesonide) is a locally-acting corticosteroid used for the treatment of inflammatory bowel disease. Losec/Prilosec (omeprazole) is used for the short- and long-term treatment of acid-related diseases. Nexium (esomeprazole magnesium) is the first proton pump inhibitor (PPI) used for the treatment of acid-related diseases to offer clinical improvements through other PPIs and other treatments. Nexium is marketed in approximately 125 countries and is available in oral (tablet, capsule and sachet for oral suspension) and intravenous dosage forms, for the treatment of acid-related diseases. Nexium is also approved for use in children from the age of one month in the U.S. and from one year in Europe and other markets. Significant Events In March 2014, AstraZeneca has announced the formation of a research partnership with Shenzhen University Health Science Center. The partnership would focus on pre-clinical research of treatments targeting chronic kidney disease (CKD) by bringing together scientists from both organisations. In April 2014, AstraZeneca announced that it had entered into a five-year early drug discovery collaboration with the UK Medical Research Council (MRC). A new research facility, the AstraZeneca MRC UK Centre for Lead Discovery, would be set up as part of the new collaboration, which is expected to be completed in 2016. In April 2014, AstraZeneca has entered into a research collaboration with Tianjin Medical University (TMU) with the aim to focus on investigating new targets against cardiac fibrosis. In June 2014, Cepheid announced a new collaboration with AstraZeneca, Cubist Pharmaceuticals Inc. and GSK intended to promote transformational change in infectious disease therapy by developing a rapid diagnostic test that can target multi-drug resistant pathogens and support the appropriate use of antibiotics. In July 2014, AstraZeneca has entered into an agreement with Max Planck Institute of Molecular Physiology for the creation of a satellite unit in cardiovascular and metabolic disease, which will be geared towards research into 'novel chemistry and chemical biology in areas of new modality chemistry, such as stabilized peptides, macrocycles, and conjugation chemistry. History The company was founded 1992. It was incorporated in England and Wales in 1992 under the Companies Act 1985. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in 1999.
astrazeneca plc-spons adr (AZN:New York)
2 Kingdom Street
London, W2 6BD
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151www.astrazeneca.com
|AbbVie Inc||$54.96 USD||-0.83|
|Bayer AG||€101.65 EUR||+0.44|
|Biogen Idec Inc||$322.22 USD||+3.10|
|Eli Lilly & Co||$62.84 USD||+0.31|
|Novo Nordisk A/S||kr249.90 DKK||+2.10|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ASTRAZENECA PLC-SPONS ADR, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.